List view / Grid view
The first and only Bruton’s tyrosine kinase (BTK) inhibitor approved…
The first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for follicular lymphoma in the EU, now has the broadest label of any medicine in its class globally.
Following the CHMP’s recommendation of a follicular lymphoma combination treatment,…
Following the CHMP’s recommendation of a follicular lymphoma combination treatment, if approved, BRUKINSA will be the first BTK inhibitor to be authorised for follicular lymphoma.
BRUKINSA® (zanubrutinib) has been authorised by the MHRA for chronic…
BRUKINSA® (zanubrutinib) has been authorised by the MHRA for chronic lymphocytic leukaemia and marginal zone lymphoma in Great Britain.
